Loading...
•
Sep 30, 2020
Evelo Q3 2020 Earnings Report
Reported third quarter financial results and business highlights
Key Takeaways
Evelo Biosciences reported its third quarter 2020 financial results, highlighting progress in clinical trials for EDP1815 in psoriasis and atopic dermatitis, as well as advancements in their SINTAX-based medicine platform. The company anticipates six clinical readouts over the next 3-9 months and is progressing with preclinical development of microbial extracellular vesicles.
Treated first patients in Phase 2 dose-ranging trial for EDP1815 in psoriasis.
Six clinical readouts in psoriasis, atopic dermatitis, COVID-19, and breast cancer expected over next 3-9 months.
Advanced newly discovered microbial extracellular vesicles as next-generation SINTAX-based medicines.
Data from Phase 1b trial evaluating EDP1815 in psoriasis spotlighted at EADV Virtual Congress.
Evelo
Evelo
Forward Guidance
Evelo expects to fund its planned operating expenses and capital expenditure requirements into the beginning of the third quarter of 2021.